$NVO plunges over 20% after slashing 2025 outlook. Weak U.S. demand for Wegovy and compounding competition expose planning and execution failures.
$NVO is still blaming their weakness on " knockoff GLP1s"😂 I like the company, but why isn't $LLY doing the same? Management has to take accountability at some point! pic.twitter.com/sLzJniQLyY — Patient Investor (@patientinvestor) July 29, 2025 The fall hit hard. Early in the morning Novo Nordisk shares dropped over 20% after slicing its full‑year …